2011 Scrip 100: Oncology trials
This article was originally published in Scrip
Executive Summary
Between 1 October 2009 and 30 September 2010, there were 428 new Phase II to Phase III clinical trials initiated by industry sponsors in the oncology arena. Non-small cell lung cancer was the clear disease focus, accounting for 11% of these new trials. Breast cancer, multiple haematological cancers, non-Hodgkin's lymphoma and colorectal cancer rounded out the top five disease areas, together accounting for 35% (147) of the total trials initiated.
You may also be interested in...
Adalvo Hails First European Launch Of Prolonged-Release Pregabalin
After the drug’s approval for use in neuropathic pain within the EU last December, Adalvo announced the analgesic’s first European launch in Germany.
Alvotech Highlights Lack Of Simponi Rivals As It Delivers Golimumab Results
Alvotech has just become the first company to announce positive topline results from a confirmatory clinical study for a proposed golimumab rival to Simponi and Simponi Aria – and moreover, the firm sees limited competition from other biosimilars on the horizon.
Xbrane Assembles The Troops As FDA Says No To Lucentis Biosimilar
Xbrane Biopharma was riding the crest of a wave with the EU launch of its biosimilar to Lucentis, following years of toil and investment. However, plans to roll out the product in the US will have to be pushed back – likely – into the middle of 2025, following a US FDA complete response letter.